‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents
WASHINGTON — A handful of newly elected Democrats, including Rashida Tlaib of Michigan, Ayanna Pressley of Massachusetts and Katie Porter of California put drug industry CEOs on the defensive Wednesday like they’ve never been before.
The trio of freshman lawmakers used an Oversight Committee hearing to press the CEOs of Teva, Celgene and Bristol-Myers Squibb — painfully and directly — on the results of an 18-month investigation into the pricing of two drugs: Teva’s Multiple Sclerosis drug copaxone and Bristol-Myers Squibb’s multiple myeloma drug revlimid.
